Tmj Treatment denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for tmj treatment are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies TMJ Treatment as Experimental — and Why You Can Appeal

Cigna's "experimental or investigational" denial for a TMJ treatment is one of the most aggressively contested denial categories. It means Cigna has determined that the requested treatment does not yet meet its standard for proven clinical benefit. These denials are among the most important to appeal because independent external reviewers regularly reach different conclusions than the original insurer reviewer.

## Why This Denial Happens

Cigna uses an internal clinical policy standard to evaluate whether a treatment has sufficient evidence of safety and efficacy for the proposed indication. For some TMJ interventions — particularly newer devices, injection therapies, or surgical techniques — Cigna may classify the treatment as experimental based on its internal policy, even if the treatment has FDA clearance or approval and is used in standard clinical practice by specialists. The gap between FDA clearance/approval and an insurer's "proven" threshold is a legitimate and common appeal ground.

## Your Federal Appeal Rights

• ACA Section 2719: Non-grandfathered plans must allow internal appeal and independent external review. External review is particularly important for experimental denials — federal law specifically requires that independent review organizations (IROs) apply objective clinical evidence standards, not just the insurer's internal policy. External review requests are generally due within approximately four months of the denial — confirm the exact deadline on your EOB.
• ERISA Section 503: Employer-plan members have full-and-fair review rights, including access to the specific clinical criteria and reviewer qualifications used in the denial.
• Expedited review: Available when delay poses a serious health risk.

## The Concrete Appeal Process

1. Request Cigna's complete denial file. Ask for the specific clinical policy used, the reviewer's credentials and specialty, and all clinical literature Cigna relied on. 2. Obtain the FDA approval or clearance documentation for the treatment, device, or drug. 3. Gather supporting guideline and literature documentation from the relevant specialty society (such as the American Academy of Orofacial Pain or the American Association of Oral and Maxillofacial Surgeons). 4. File the internal appeal with a specialist-authored medical-necessity letter and supporting documentation. 5. Request external review — this is especially critical for experimental denials, as IROs are required to use objective standards.

## Documentation to Gather

• Regulatory status: FDA approval or clearance documentation for the specific product or procedure.
• Specialty society guidelines: Current clinical practice guidelines from the relevant professional organization endorsing the treatment for this indication (reference the organization generically; you do not need to cite specific numbers).
• Clinical basis: Chart notes, imaging, and specialist evaluation documenting why this treatment is indicated for this patient's specific presentation.
• Specialist medical-necessity letter: Written by a clinician with expertise in orofacial pain or TMJ disorders, addressing Cigna's specific experimental criteria and explaining why the treatment is consistent with accepted clinical practice for this patient.

## Criteria-Mapping Structure

Create a side-by-side table:

| Cigna's Experimental/Investigational Criterion | Your Rebuttal Evidence | |---|---| | Copy each criterion verbatim from Cigna's clinical policy | Enter the regulatory document, guideline reference, or prescriber statement that directly addresses it |

External reviewers overturn experimental denials at a meaningful rate when the clinical record shows that recognized specialty societies endorse the treatment and the FDA has acted on the product. Do not stop at internal appeal — file for external review even if the internal process is upheld.